ClinicalTrials.gg
Not yet recruitingNCT07270393Updated Dec 8, 2025

Study of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis.

An interventional study of Diet supplementation in Endometriosis, sponsored by Biogipuzkoa Health Research Institute. Not yet recruiting at 1 site in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Biogipuzkoa Health Research Institute · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.

Planned enrollment
15th of 33
104 · median 90
Started
2025
with 5 others
No phase
18 of 42
8 open now
Primary completion
2026-12
later than 6 of 14 live
Registered
38th of 42
by date

Among the 42 studies in Endometriosis with a site in Spain, this one is the 15th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2025, is one of 18 with no phase, reaches primary completion later than 6 of the 14 other live ones, and was the 38th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Endometriosis with a site in Spain, or all of them as a file.
02

Study summary

The severities of chronic disease symptoms correlate with the levels of analytical parameters of inflammation. Studies have been published in which the Mediterranean diet has an anti-inflammatory phenomenon, decreasing inflammation parameters. This decrease correlates with an improvement in symptoms.

Endometriosis is a chronic inflammatory disease and the influence of the Mediterranean diet on the decrease of inflammation parameters in women with endometriosis has been studied.

The studies carried out to assess whether this decrease in inflammatory parameters correlates with clinical improvement and quality of life in these patients have low/very low scientific evidence (small sample size, no control group) and with different interventions (diets, restrictions and/or supplements), which prevent their analysis as a whole.

Therefore, our hypothesis is that the Mediterranean diet, due to its anti-inflammatory effect, can improve the symptomatology and quality of life of patients with endometriosis.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • Mediterranean diet
  • Quality of life
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female.
  • Age 18-45.
  • Premenopausal status.
  • Radiological diagnosis (by transvaginal ultrasound and/or MRI) and/or surgical diagnosis of endometriosis.
  • Follow-up in the Gynecology Department of OSI Donostia (at least 1 visit in the last year).
  • Clinical score of at least 3/10 on the Numerical Scale in at least one symptom related to endometriosis).
  • Possibility of understanding Spanish.
  • Possibility of understanding the indicated dietary recommendations.
  • Acceptance of inclusion in clinical study, by signing .

Exclusion criteria

EXCLUSION CRITERIA:

  • Diagnosis of Eating Disorder.
  • Diagnosis of malabsorptive syndromes: Chron's disease, Ulcerative colitis, short bowel syndrome, gastric by-pass, irritable bowel.
  • Other concomitant diseases that produce CPD.
  • diseases.-
  • Metabolic diseases requiring follow-up of specific diets.
  • Diagnosed gluten intolerance.
  • Vegan diet.
  • Follow-up by a nutritionist.
  • Diagnosis of severe mental illness requiring treatment.
  • Pregnancy or current breastfeeding.
  • Active cancer process.
  • Personal history of gynecologic or digestive oncologic process.
  • Change of treatment or surgery during follow-up.
  • Surgery related to endometriosis or change of treatment in the 6 weeks prior to enrollment in the study.
  • Drug abuse. Opioid analgesia \< 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
104 participants (estimated)

Study arms

  • No intervention
    Control Group

    This group will not receive normocaloric Mediterranean diet recommendations.

  • Experimental
    Intervention Group

    This group will receive a series of normocaloric Mediterranean diet recommendations.

    Other: Diet supplementation

Interventions

  • OtherDiet supplementation

    The severities of chronic disease symptoms correlate with the levels of analytical parameters of inflammation. Studies have been published in which the Mediterranean diet has an anti-inflammatory phenomenon, decreasing inflammation parameters. This decrease correlates with an improvement in symptoms . Endometriosis is a chronic inflammatory disease and the influence of the Mediterranean diet on the decrease of inflammation parameters in women with endometriosis has been studied.

06

What researchers measure

Primary outcomes

  1. Quality of life and endometriosis.

    Endometriosis Health Profile 30 (EHP-30) questionnaire (0-100)

    Time frame: 24 weeks

  2. Pain intensity in symptoms related to endometriosis

    Pain with menstruation or Dysmenorrhea - A numeric scale (0-10)

    Time frame: 24 weeks

  3. Pain intensity in symptoms related to endometriosis

    Pain with sexual intercourse or Dyspareunia - A numeric scale (0-10)

    Time frame: 24 weeks

  4. Pain intensity in symptoms related to endometriosis

    Pain with defecation or Dyschezia - A numeric scale (0-10)

    Time frame: 24 weeks

  5. Pain intensity in symptoms related to endometriosis

    Pain with urination or Dysuria - A numeric scale (0-10)

    Time frame: 24 weeks

  6. Pain intensity in symptoms related to endometriosis

    Non-menstrual pelvic pain - A numeric scale (0-10)

    Time frame: 24 weeks

  7. Pain intensity in symptoms related to endometriosis

    Abdominal bloating or distension - A numeric scale (0-10)

    Time frame: 24 weeks

  8. Pain intensity in symptoms related to endometriosis

    Tiredness - A numeric scale (0-10)

    Time frame: 24 weeks

Secondary outcomes

  1. General Quality of Life

    WHOQOL-BREF questionnaire. (0-100)

    Time frame: 24 weeks

  2. Use of analgesics

    Collecting the use of analgesics.

    Time frame: 24 weeks

  3. Change in BMI

    Abdominal and hip circumference. (cm)

    Time frame: 24 weeks

  4. Diet quality

    Diet Quality Assessment Survey developed by the Spanish Society of Dietetics and Food Sciences (SEDCA).

    Time frame: 24 weeks

  5. Adherence to the Mediterranean diet

    Diet adherence test, used in the PREDIMED study, available free of charge on the website of the Spanish Society of Dietetics and Food Sciences (SEDCA).

    Time frame: 24 weeks

  6. Satisfaction Survey

    Brief questionnaire that seeks to know the patient's opinion about his or her experience and degree of satisfaction with different aspects of the study.

    Time frame: 24 weeks

Other outcomes

  1. Personal data

    Date and place of birth.

    Time frame: 24 weeks

  2. Personal data

    Number of children.

    Time frame: 24 weeks

  3. Physical examination

    Weight (kg)

    Time frame: 24 weeks

  4. Physical examination

    Height (cm)

    Time frame: 24 weeks

  5. Physical examination

    Body Mass Index (BMI) (kg/m2)

    Time frame: 24 weeks

  6. Physical examination

    Abdominal circumference. (cm)

    Time frame: 24 weeks

  7. Physical examination

    Hip circumference (cm)

    Time frame: 24 weeks

  8. Obstetric history

    Assisted reproduction treatments (Current/completed/future)

    Time frame: 24 weeks

  9. Obstetric history

    Gestational desire

    Time frame: 24 weeks

  10. Medical history related to endometriosis

    Type of endometriosis (Not reported/ Ovarian endometriosis/ Deep endometriosis/ Endometriosis)

    Time frame: 24 weeks

  11. Medical history related to endometriosis

    Diagnosis of endometriosis by: radiology and/or surgery.

    Time frame: 24 weeks

  12. Medical history related to endometriosis

    Previous diets performed.

    Time frame: 24 weeks

  13. Medical history related to endometriosis

    Treatments received: Medical (hormonal contraception, analogues, other).

    Time frame: 24 weeks

  14. Medical history related to endometriosis

    Treatments received: Surgical (conservative vs. radical surgery).

    Time frame: 24 weeks

  15. Current situation related to endometriosis

    Symptoms.

    Time frame: 24 weeks

  16. Current situation related to endometriosis

    Current treatment.

    Time frame: 24 weeks

  17. Medical history related to endometriosis

    Diagnosis: Date- time of evolution since onset of symptom.

    Time frame: 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 8, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07270393
Lead sponsor
Biogipuzkoa Health Research Institute
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 8, 2025

Study contacts

Jone Paredes Goenaga JONE.PAREDESGOENAGA@osakidetza.eus, Ginecology and Obstetrics
Contact
JONE.PAREDESGOENAGA@osakidetza.eus
943007478

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion